290 related articles for article (PubMed ID: 32111095)
1. Acid Ceramidase Depletion Impairs Neuronal Survival and Induces Morphological Defects in Neurites Associated with Altered Gene Transcription and Sphingolipid Content.
Kyriakou K; Lederer CW; Kleanthous M; Drousiotou A; Malekkou A
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111095
[TBL] [Abstract][Full Text] [Related]
2. ASAH1-related disorders: Description of 15 novel pediatric patients and expansion of the clinical phenotype.
Mahmoud IG; Elmonem MA; Zaki MS; Ramadan A; Al-Menabawy NM; El-Gamal A; Mansour L; Issa MY; Abdel-Hamid MS; Abdel-Hady S; Khalifa I; Ibrahim A; Solyom A; Rolfs A; Selim L
Clin Genet; 2020 Dec; 98(6):598-605. PubMed ID: 32875576
[TBL] [Abstract][Full Text] [Related]
3. Spinal muscular atrophy associated with progressive myoclonus epilepsy.
Topaloglu H; Melki J
Epileptic Disord; 2016 Sep; 18(S2):128-134. PubMed ID: 27647482
[TBL] [Abstract][Full Text] [Related]
4. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy.
Elsea SH; Solyom A; Martin K; Harmatz P; Mitchell J; Lampe C; Grant C; Selim L; Mungan NO; Guelbert N; Magnusson B; Sundberg E; Puri R; Kapoor S; Arslan N; DiRocco M; Zaki M; Ozen S; Mahmoud IG; Ehlert K; Hahn A; Gokcay G; Torcoletti M; Ferreira CR
Hum Mutat; 2020 Sep; 41(9):1469-1487. PubMed ID: 32449975
[TBL] [Abstract][Full Text] [Related]
5. Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy.
Gan JJ; Garcia V; Tian J; Tagliati M; Parisi JE; Chung JM; Lewis R; Baloh R; Levade T; Pierson TM
Neuromuscul Disord; 2015 Dec; 25(12):959-63. PubMed ID: 26526000
[TBL] [Abstract][Full Text] [Related]
6. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
[TBL] [Abstract][Full Text] [Related]
7. Acid ceramidase deficiency: Farber disease and SMA-PME.
Yu FPS; Amintas S; Levade T; Medin JA
Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
[TBL] [Abstract][Full Text] [Related]
9. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
[TBL] [Abstract][Full Text] [Related]
10. Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expression.
Lucki NC; Bandyopadhyay S; Wang E; Merrill AH; Sewer MB
Mol Endocrinol; 2012 Feb; 26(2):228-43. PubMed ID: 22261821
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for the activation of acid ceramidase.
Gebai A; Gorelik A; Li Z; Illes K; Nagar B
Nat Commun; 2018 Apr; 9(1):1621. PubMed ID: 29692406
[TBL] [Abstract][Full Text] [Related]
12. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.
Kleynerman A; Rybova J; Faber ML; McKillop WM; Levade T; Medin JA
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830643
[TBL] [Abstract][Full Text] [Related]
13. The molecular medicine of acid ceramidase.
Frohbergh M; He X; Schuchman EH
Biol Chem; 2015 Jun; 396(6-7):759-65. PubMed ID: 25938220
[TBL] [Abstract][Full Text] [Related]
14. Spinal muscular atrophy and Farber disease due to ASAH1 variants: A case report.
Lee BH; Mongiovi P; Levade T; Marston B; Mountain J; Ciafaloni E
Am J Med Genet A; 2020 Oct; 182(10):2369-2371. PubMed ID: 32627310
[TBL] [Abstract][Full Text] [Related]
15. Arterial Medial Calcification through Enhanced small Extracellular Vesicle Release in Smooth Muscle-Specific Asah1 Gene Knockout Mice.
Bhat OM; Li G; Yuan X; Huang D; Gulbins E; Kukreja RC; Li PL
Sci Rep; 2020 Feb; 10(1):1645. PubMed ID: 32015399
[TBL] [Abstract][Full Text] [Related]
16. Farber disease in a patient from China.
Bao X; Ma M; Zhang Z; Xu Y; Qiu Z
Am J Med Genet A; 2020 Sep; 182(9):2184-2186. PubMed ID: 32706452
[TBL] [Abstract][Full Text] [Related]
17. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy.
Schuchman EH
Biochim Biophys Acta; 2016 Sep; 1862(9):1459-71. PubMed ID: 27155573
[TBL] [Abstract][Full Text] [Related]
18. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes.
Li CM; Park JH; Simonaro CM; He X; Gordon RE; Friedman AH; Ehleiter D; Paris F; Manova K; Hepbildikler S; Fuks Z; Sandhoff K; Kolesnick R; Schuchman EH
Genomics; 2002 Feb; 79(2):218-24. PubMed ID: 11829492
[TBL] [Abstract][Full Text] [Related]
19. ASAH1 variant causing a mild SMA phenotype with no myoclonic epilepsy: a clinical, biochemical and molecular study.
Filosto M; Aureli M; Castellotti B; Rinaldi F; Schiumarini D; Valsecchi M; Lualdi S; Mazzotti R; Pensato V; Rota S; Gellera C; Filocamo M; Padovani A
Eur J Hum Genet; 2016 Nov; 24(11):1578-1583. PubMed ID: 27026573
[TBL] [Abstract][Full Text] [Related]
20. Spinal muscular atrophy with progressive myoclonic epilepsy linked to mutations in ASAH1.
Yildiz EP; Yesil G; Bektas G; Caliskan M; Tatlı B; Aydinli N; Ozmen M
Clin Neurol Neurosurg; 2018 Jan; 164():47-49. PubMed ID: 29169047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
